Results 221 to 230 of about 1,753,858 (323)

Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility

open access: yesAntimicrobial Agents and Chemotherapy, 1990
L. Rice   +6 more
semanticscholar   +1 more source

Species‐Specific Optimisation and Environmental Regulation of Biofilm Formation in Enterobacter cloacae: Inhibitory Role of Glucose in Biofilm Development

open access: yesEnvironmental Microbiology Reports, Volume 18, Issue 3, June 2026.
This study demonstrates that mild salinity stress (1%–2% NaCl) significantly enhances biofilm formation in Enterobacter cloacae. Using a standardised 96‐well microtiter plate assay, we optimised in vitro biofilm quantification and classification, providing a reproducible framework for studying environmental and clinical biofilm development mechanisms ...
Srishti Singh   +6 more
wiley   +1 more source

A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates.

open access: yesJournal of Antimicrobial Chemotherapy, 2010
A. Tsakris   +7 more
semanticscholar   +1 more source

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 11, Page 1487-1494, June 2026.
This multicenter, observational study reveals distinct alterations in the microbial spectrum of spontaneous bacterial peritonitis (SBP) associated with proton pump inhibitor use. These results are especially relevant for guiding empiric antibiotic therapy of SBP.
Philip Kitchen   +13 more
wiley   +1 more source

Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley   +1 more source

Home - About - Disclaimer - Privacy